Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: A prespecified secondary analysis of the FOURIER trial

Giugliano, Robert P.;Pedersen, Terje R.;Park, Jeong-Gun;De Ferrari, Gaetano M.;Gaciong, Zbigniew A.;Ceska, Richard;Toth, Kalman;Gouni-Berthold, Ioanna;Lopez-Miranda, Jose;Schiele, François;Mach, François;Ott, Brian R.;Kanevsky, Estella;Pineda, Armando Lira;Somaratne, Ransi;Wasserman, Scott M.;Keech, Anthony C.;Sever, Peter S.;Sabatine, Marc S.

2017-01-01